10x Genomics, CHUV Partner on Single Cell Cancer Biomarker Study
10x Genomics and Lausanne University Hospital (CHUV) launched a research collaboration to advance diagnostic applications of single cell…
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced…
FDA approves Pluvicto for PSMA+ metastatic
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced…
FDA Approves Roche PTEN Assay for Prostate Cancer Protein Deficiency
Roche announced that the Food and Drug Administration (FDA) approved the Ventana PTEN (SP218) RxDx Assay, an immunohistochemistry…
How This Former Army Officer Helps Deliver Cancer Treatments to Patients, Through Hurricanes and Beyond
What was it about radioligand therapy that interested you in particular? I had made a connection at another…
Novartis Adds New Therapies As Shares Trade Below Analyst Value Targets
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Novartis Rhapsido® receives European Commission approval
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
Novartis Expands Cancer Drug Portfolio with $3 Billion Acquisition
In a strategic move to bolster its cancer medication offerings, Novartis has entered into a definitive agreement…
Novartis to buy experimental breast cancer drug in up to $3 billion deal
FRANKFURT, March 20 (Reuters) – Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate…
25 Year Anniversary of Innovation in Treating CML
Twenty-Five Years of Community: How Living With CML Has Changed—and Brought Patients Together Discussion notes from the Second…
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe…